|
CXORF38 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.66133814775094E-16 |
| Normal-vs-Stage2 |
2.36010000431719E-08 |
| Normal-vs-Stage3 |
5.1592063954331E-13 |
| Normal-vs-Stage4 |
6.52244924737033E-12 |
| Stage1-vs-Stage2 |
8.208800E-01 |
| Stage1-vs-Stage3 |
4.104600E-01 |
| Stage1-vs-Stage4 |
8.037500E-02 |
| Stage2-vs-Stage3 |
7.412600E-01 |
| Stage2-vs-Stage4 |
2.578600E-01 |
| Stage3-vs-Stage4 |
3.145400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
4.23940000000567E-05 |
| Normal-vs-Asian |
3.29649640917751E-11 |
| Caucasian-vs-AfricanAmerican |
4.540200E-01 |
| Caucasian-vs-Asian |
2.532800E-01 |
| AfricanAmerican-vs-Asian |
1.276430E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.29118937763906E-13 |
| Normal-vs-Female |
1.62525548574877E-12 |
| Male-vs-Female |
3.783300E-03 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.8917090116588E-12 |
| Normal-vs-Age(41-60Yrs) |
8.4821039081362E-14 |
| Normal-vs-Age(61-80Yrs) |
1.30928601294045E-12 |
| Normal-vs-Age(81-100Yrs) |
4.351600E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.917000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.671800E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.891200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.243770E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.830800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.690400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.136200E-01 |
| Classical-VS-Follicular |
1.763030E-01 |
| Classical-VS-Other |
5.993900E-02 |
| Classical-VS-Normal |
3.54099971566768E-10 |
| Tall-VS-Follicular |
9.565600E-01 |
| Tall-VS-Other |
1.278640E-01 |
| Tall-VS-Normal |
1.12859999124026E-09 |
| Follicular-VS-Other |
2.932600E-01 |
| Follicular-VS-Normal |
5.78289638397678E-11 |
| Other-VS-Normal |
5.99589999999983E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.10782519111308E-15 |
| Normal-vs-N1 |
1.04239950005081E-11 |
| N0-vs-N1 |
1.579370E-01 |
|
|
